5 Key Insights into the FDA's New Acting Vaccine and Biologics Director

The U.S. Food and Drug Administration has appointed Dr. Katherine Szarama as the acting director of its Center for Biologics Evaluation and Research (CBER), a pivotal agency that oversees vaccines, gene therapies, and the national blood supply. This move comes after the departure of Dr. Vinay Prasad, whose tenure was marked by contentious decisions on rare disease treatments and vaccines. Here are five essential things to know about this leadership change and what it means for biologics regulation.

1. What is CBER and why does it matter?

The Center for Biologics Evaluation and Research is a critical arm of the FDA responsible for ensuring the safety and effectiveness of biological products. These include vaccines (like those for COVID-19, flu, and RSV), gene therapies that modify a patient’s DNA to treat diseases, and the blood supply used in transfusions. CBER also regulates allergenic extracts and cellular therapies. Its decisions have a direct impact on public health, from pandemic response to rare disease treatments. With Szarama stepping in, the center maintains continuity in oversight while navigating complex scientific and regulatory challenges.

2. Who is Katherine Szarama?

Katherine Szarama, Ph.D., is a veteran FDA scientist with deep expertise in biologics. She has served within CBER for years, most recently in leadership roles focusing on product evaluation and policy. Her background includes research on immune responses and vaccine development, making her well-suited to guide the center through ongoing debates on vaccine safety and gene therapy approvals. Associates describe her as a thoughtful regulator who prioritizes data-driven decisions. Her appointment as acting director signals the agency’s commitment to maintaining experienced leadership during a period of transition.

3. Why did Vinay Prasad leave?

Vinay Prasad, the previous CBER director, left the FDA on Thursday after a tenure characterized by controversy. He was known for questioning the approval of certain rare disease drugs and for taking a skeptical stance on vaccine mandates and boosters. These positions clashed with broader public health strategies. In March, FDA Commissioner Marty Makary announced that Prasad would return to the University of California, San Francisco, where he holds a faculty position. His abrupt departure has left some industry stakeholders concerned about policy direction, though Szarama’s experience is expected to provide stability.

4. What immediate changes can we expect?

With Szarama at the helm, CBER is unlikely to shift dramatically in the short term. She inherits a full agenda, including ongoing reviews of next-generation COVID-19 vaccines, updates to blood donation guidelines, and oversight of new gene therapies for sickle cell disease and hemophilia. Her acting role allows the FDA to continue operations while a permanent director is sought. Observers anticipate she will maintain the agency’s current scientific rigor, though her leadership style may bring more collaborative decision-making. No major policy reversals are expected immediately.

5. How does this affect the future of vaccine regulation?

Vaccine regulation remains a hot-button issue. Szarama steps in as the FDA faces pressure to accelerate or refine approval pathways for vaccines targeting evolving viruses. Her appointment ensures continuity in safety monitoring and efficacy standards. Gene therapy regulation is also expanding, with more products seeking approval for rare genetic conditions. Szarama’s background in immune responses positions her to balance innovation with patient safety. The coming months will show whether she maintains the independent, science-focused approach that CBER is known for, or if external pressures from the administration influence decisions.

In conclusion, the appointment of Katherine Szarama as acting director of CBER marks a transitional moment for the agency. While her experience provides reassurance, the long-term direction will depend on who is chosen as permanent director and how the agency navigates emerging challenges in vaccines, gene therapies, and blood safety. For now, the FDA continues its critical work under steady leadership.